Floatz logo

Surufatinib

Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.Small moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Epirubicin
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Cyclophosphamide
Beijing Biotech
Phase 1/2B
Eloxatin
ASLAN Pharmaceuticals
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 1/2CCC

View all 50 →

Same molecule, other indications

Surufatinib is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →